Semaglutide

Most peptides on this site are like a promising lab-notebook entry. Semaglutide is the opposite: it is the textbook chapter. The science is settled, the medicine is on pharmacy shelves, and the trials are landmark-grade. The proof belongs to the real, regulated product. Buying an unlabelled vial online is like ordering a brand-name part from a stranger's garage and assuming it is genuine.

Selective agonist at the GLP-1 receptor (class B G-protein-coupled receptor). It enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and activates appetite-regulating neurons in the hypothalamus and area postrema, reducing hunger and energy intake. Structural modifications (an Aib substitution at position 8 for DPP-4 resistance and a fatty-acid linker for albumin binding) extend its half-life to roughly one week. Administered subcutaneously (Ozempic/Wegovy) or orally with an absorption enhancer (Rybelsus).

Research contexts. Not proven uses, and not recommendations.

Extensive and high quality. Multiple large, double-blind, placebo- and active-controlled RCTs across diabetes (SUSTAIN, PIONEER) and obesity (STEP). STEP 1 (n=1,961) showed mean weight loss of about 14.9% versus 2.4% on placebo over 68 weeks. The SELECT trial (n=17,604) showed a 20% relative reduction in major adverse cardiovascular events in people with obesity and prior cardiovascular disease without diabetes. This is among the best-evidenced agents in metabolic medicine. The evidence applies to the licensed, quality-controlled product, not to unbranded grey-market vials of unverified contents, dose accuracy and purity.

• !Very common gastrointestinal side effects: nausea, vomiting, diarrhoea, constipation, especially during dose escalation
• !Risk of gallbladder disease and a recognised (though uncommon) acute pancreatitis signal
• !Rodent thyroid C-cell tumour signal; contraindicated in personal or family history of medullary thyroid carcinoma or MEN2
• !Loss of lean muscle and bone mass can accompany rapid weight loss. Weight regain is common after discontinuation
• !Reports of aspiration risk under anaesthesia due to delayed gastric emptying
• !GREY MARKET: large volumes of unlicensed 'research' semaglutide are sold online 'not for human consumption' with no guarantee of identity, dose accuracy, sterility or purity; counterfeit pens and mislabelled vials are a documented problem
• !Not for use in pregnancy; should be stopped before planned conception
• !Prescription-only: self-sourcing bypasses the gradual dose titration and medical screening that mitigate the real risks

A fully licensed UK medicine, prescription-only (POM), regulated by the MHRA. Marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management). In 2026 the MHRA became the first regulator to approve the highest-strength single-dose Wegovy pen for adults with obesity, and Wegovy is also approved to reduce cardiovascular risk in eligible adults. NICE recommends Wegovy on the NHS within specialist weight-management services for defined BMI thresholds. Ozempic is restricted to diabetes to protect supply and should not be prescribed solely for weight loss. Legitimate access is via prescription. Unbranded semaglutide sold online as a 'research chemical' is unlicensed, of unverified quality, and falls entirely outside regulatory oversight.

• NCT03548935· Phase 3· Completed

  STEP 1: Semaglutide in adults with overweight or obesity

  Pivotal obesity efficacy trial underpinning Wegovy.

• NCT03574597· Phase 3· Completed

  SELECT: Semaglutide effects on cardiovascular outcomes in obesity without diabetes

  Demonstrated 20% MACE reduction; basis for CV risk-reduction indication.

• NCT01720446· Phase 3· Completed

  SUSTAIN-6: Cardiovascular and long-term outcomes with semaglutide in type 2 diabetes

  Cardiovascular safety/outcomes in type 2 diabetes.

1. 01
   Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — Wilding JPH, et al., New England Journal of Medicine (2021)

   Pivotal obesity RCT; ~14.9% mean weight loss vs 2.4% placebo at 68 weeks.

2. 02
   Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — Lincoff AM, et al., New England Journal of Medicine (2023)

   17,604 patients; 20% relative reduction in major adverse cardiovascular events.

3. 03
   Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — Marso SP, et al., New England Journal of Medicine (2016)

   Cardiovascular safety/outcomes trial in type 2 diabetes.

4. 04
   Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity, MHRA / GOV.UK (2026)

   UK regulatory status; MHRA first regulator to approve the highest-strength Wegovy pen.